retatrutide joint pain (Eli Lilly's triple GLP-1/GIP/Glucagon receptor agonist) just delivered the most impressive obesity + osteoarthritis data we've ever seen in the phase 3 TRIUMPH-4 trial: TRIUMPH-4: Retatrutide Delivers Weight Loss,

In particular, GLP-1 analogues have shown direct effects on the plasticity of the pancreatic islet in both normal glucose tolerance and throughout the whole spectrum of alterations leading to overt diabetes [7]

The three medications share most safety considerations, with two categories to distinguish: FDA-labeled contraindications These are absolute

HPLC analysis of reconstituted peptide solutions typically shows measurable purity decline beginning around week three, with more significant degradation after week four

In rodent studies, liraglutide caused dose-dependent thyroid C-cell tumors, including medullary thyroid carcinoma (MTC)